![Oxford Biomedica 2019 2.jpg](https://www.bioindustry.org/static/uploaded/6f2bc54a-4523-4d80-bbc934eacaf5185b.jpg)
Oxford Biomedica plc
R&D/Manufacturing
- Website
- https://www.oxb.com/
- Membership category
- Corporate
Windrush Court, Transport Way, Oxford, OX4 6LT,
Oxford Biomedica plc at a glance
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs.
About Oxford Biomedica plc
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company’s technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, VIRxSYS, Emergent BioSolutions and ImaginAb. Oxford BioMedica is headquartered in Oxford, UK, where it also owns a manufacturing facility and has an office in San Diego, California.